Remicade Patent Fails Reexamination After Mysterious Assault At PTO
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J’s rheumatoid arthritis drug could see biosimilar competition before 2018 after an unnamed sponsor got the patent office to take another look at the specificity of the description.
You may also be interested in...
Lessons From The First Biosimilar MAb Launch In Europe
Physicians appear more willing to prescribe Hospira’s Inflectra, a biosimilar version of J&J’s Remicade, to new patients in countries in Europe where it is available, but less inclined to switch patients already taking the brand. The company’s experience in Europe could offer lessons for manufacturers looking to bring biosimilars to market in the US.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.